PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat infections in chronic and acute wounds, announced today that NYSE Arca options initiated the trading of options on Oculus Innovative Sciences on June 16, 2009.
